- Enobosarm 3mg combined with semaglutide resulted in 99.1% of weight loss from fat while preserving lean mass and demonstrated fewer gastrointestinal side effects.
- The treatment showed a 62.4% reduction in patients experiencing a decline in physical function compared to semaglutide alone.
- No serious treatment-related adverse events were reported in the study.
Veru Inc. (VERU, Financial) announced positive safety results from its Phase 2b QUALITY clinical trial, highlighting the benefits of combining enobosarm 3mg with semaglutide (Wegovy®) for weight management. The study revealed that this combination leads to highly selective fat loss while preserving muscle mass.
The clinical trial exhibited impressive results with 99.1% of total weight loss deriving from fat mass, a significant improvement over semaglutide alone. Additionally, the inclusion of enobosarm led to fewer gastrointestinal side effects, reducing instances of nausea, GERD, and diarrhea compared to those receiving only semaglutide.
Importantly, the trial data showed a 62.4% reduction in the number of patients experiencing a decline in physical function when using the enobosarm 3mg combination. There were no reported serious treatment-related adverse events, underscoring the safety of the regimen.
Following these promising outcomes, Veru plans to advance the 3mg dose to Phase 3 trials and has requested an End of Phase 2 meeting with the FDA, anticipated for the third quarter of 2025. The company is developing a novel modified-release formulation of enobosarm, expected to offer potential patent protection until 2045.
